ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ:ACAD
Want to see ACAD full AI Analyst Report?
ACAD Stock Chart & Stats
$22.17
-$0.09(-0.52%)
At close: 4:00 PM EST
$22.17
-$0.09(-0.52%)
Day’s Range― - ―
52-Week Range$19.69 - $28.35
Previous CloseN/A
Volume443.16K
Average Volume (3M)1.86M
Market Cap
$3.61B
Enterprise Value$3.38B
Total Cash (Recent Filing)$851.46M
Total Debt (Recent Filing)$50.79M
Price to Earnings (P/E)260.9
Beta1.14
Next Earnings
Aug 11, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.23
Shares Outstanding171,235,870
10 Day Avg. Volume1,706,802
30 Day Avg. Volume1,857,516
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)3.69
Price to Sales (P/S)4.22
P/FCF Ratio43.02
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue3.09
Enterprise Value/Gross Profit3.38
Enterprise Value/Ebitda32.34
Forecast
1Y Price Target
$32.07Price Target Upside44.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)0.39
Revenue Forecast (FY)$1.24B
Bulls Say, Bears Say
Bulls Say
Commercial ExpansionAn expanded salesforce for Nuplazid and Daybue STIX is expected to increase coverage of key prescribers and broaden patient reach, supporting sustained commercial momentum.
Pipeline ReadoutsA pivotal clinical readout for remlifanserin in Alzheimer's psychosis could provide meaningful upside if it demonstrates efficacy and a safety profile similar to Nuplazid, offering clinicians a safer on‑label alternative to current antipsychotics.
Product Formulation And Patient AccessA powder formulation of Daybue STIX is expected to improve tolerability and broaden patient access by addressing volume, taste, and excipient‑related gastrointestinal issues that limited the liquid version.
Bears Say
European Regulatory RiskA negative opinion from a European regulator and the need for re‑examination could delay or lower the chance of trofinetide and Daybue approvals in the EU, creating uncertainty for international revenue.
Rebate Headwinds And Revenue PressureLarger‑than‑expected rebate expenses have weakened reported Nuplazid sales and can obscure underlying demand strength, pressuring near‑term revenue results.
Rising Operating ExpensesProjected increases in selling, general and administrative expenses and research and development spending are larger than analysts expected, creating near‑term cost pressure on profitability.
ACADIA Pharmaceuticals News
ACAD FAQ
What was ACADIA Pharmaceuticals Inc.’s price range in the past 12 months?
ACADIA Pharmaceuticals Inc. lowest stock price was $19.69 and its highest was $28.35 in the past 12 months.
What is ACADIA Pharmaceuticals Inc.’s market cap?
ACADIA Pharmaceuticals Inc.’s market cap is $3.61B.
When is ACADIA Pharmaceuticals Inc.’s upcoming earnings report date?
ACADIA Pharmaceuticals Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 79 days.
How were ACADIA Pharmaceuticals Inc.’s earnings last quarter?
ACADIA Pharmaceuticals Inc. released its earnings results on May 06, 2026. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.051 by -$0.031.
Is ACADIA Pharmaceuticals Inc. overvalued?
According to Wall Street analysts ACADIA Pharmaceuticals Inc.’s price is currently Undervalued.
Does ACADIA Pharmaceuticals Inc. pay dividends?
ACADIA Pharmaceuticals Inc. does not currently pay dividends.
What is ACADIA Pharmaceuticals Inc.’s EPS estimate?
ACADIA Pharmaceuticals Inc.’s EPS estimate is 0.06.
How many shares outstanding does ACADIA Pharmaceuticals Inc. have?
ACADIA Pharmaceuticals Inc. has 171,235,870 shares outstanding.
What happened to ACADIA Pharmaceuticals Inc.’s price movement after its last earnings report?
ACADIA Pharmaceuticals Inc. reported an EPS of $0.02 in its last earnings report, missing expectations of $0.051. Following the earnings report the stock price went up 5.028%.
Which hedge fund is a major shareholder of ACADIA Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in ACAD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ACADIA Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.07 (44.66% Upside)
$32.07 (44.66% Upside)
Blogger Sentiment
Bullish
ACAD Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 149.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.08%
12-Months-Change
Fundamentals
Return on Equity
35.65%
Trailing 12-Months
Asset Growth
41.76%
Trailing 12-Months
Company Description
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
ACAD Company Deck
ACAD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive commercial and pipeline picture: solid Q1 revenue growth (+11% adjusted), robust DAYBUE momentum (+20% YoY) and encouraging early uptake of the DAYBUE STIX formulation, continued demand and referral gains for NUPLAZID, a strong cash position ($851M) and major near‑term clinical catalysts (remlifanserin Phase II readout and trofinetide Japan Phase III). Headwinds include a temporary refill timing disruption that impacted Q1 NUPLAZID revenue timing, a sizable near‑term increase in SG&A (+35.3% YoY) to fund commercial expansion, ongoing regulatory uncertainty in Europe for trofinetide, and an R&D leadership transition. On balance, the positives (top‑line growth, product launches, reaffirmed guidance, pipeline catalysts and healthy cash) outweigh the challenges, which management describes largely as temporary or strategic investments.View all ACAD earnings summariesACAD Stock 12 Month Forecast
Average Price Target
$32.07
▲(44.66% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
PTC Therapeutics
―
Krystal Biotech
―
MoonLake Immunotherapeutics
―
―
Ownership Overview
23.27% Insiders
15.71% Mutual Funds
3.86% Other Institutional Investors
34.78% Public Companies and
Individual Investors